Australia\'s TGA [1](#Fn1){ref-type="fn"} is advising healthcare professionals and consumers of the potential changes in the sense of taste (taste disturbance) with *Andrographis paniculata*-containing products.

*Andrographis paniculata* (hereafter Andrographis) is a herbal ingredient that is permitted for use in low-risk medicines in Australia. There are approximately 100 Andrographis-containing medicines listed in the Australian Register of Therapeutic Goods (ARTG).

The TGA noted that since mid-2019, it had \"*identified a significant increase in the number of adverse event reports involving Andrographis and the development of taste disturbance*\". The majority of these reports were linked with a multi-ingredient product (including Andrographis), which is known as Armaforce. The agency has collaborated with the Armaforce sponsor to add a product label warning regarding potential cases of taste disturbance, including the complete loss of taste. However, the TGA highlighted that its investigation of this issue \"*indicates that Andrographis is likely to be responsible for these effects on the sense of taste*\".

The onset of such taste disturbance often occurs after 2 weeks\' use of Andrographis-containing products, but can occur within a shorter timeframe. Data received from the reports received by the TGA have indicated that it can take up to several weeks after stopping the Andrographis product for a patient\'s taste to return to normal. Furthermore, there were some cases where patients had not regained a normal sense of taste at the time of reporting.

Finally, the TGA presented important information stating that \"*sudden onset of loss of taste or altered taste may be a symptom of a serious medical condition, including COVID-19. Anyone experiencing loss of taste should seek assessment by a healthcare professional, or call the National Coronavirus Helpline*\".

TGA = Therapeutic Goods Administration
